Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
What's Behind The Surge In Zentalis Stock?
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Almitas Capital LLC
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026
Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary
Zentalis (ZNTL) Q2 Loss Narrows 70%
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL